Articles from China Medical System Holdings Limited
China Medical System's Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial
By China Medical System Holdings Limited · Via ACN Newswire · November 19, 2026
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
By China Medical System Holdings Limited · Via ACN Newswire · November 4, 2026
CMS: Initial Prescriptions for Silevimig Injection, the World's First Bispecific Antibody Against Rabies, Issued in China
By China Medical System Holdings Limited · Via ACN Newswire · September 9, 2026
CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)
By China Medical System Holdings Limited · Via ACN Newswire · September 3, 2026
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World's First Bispecific Antibody for Passive Immunization Against Rabies
By China Medical System Holdings Limited · Via ACN Newswire · June 22, 2026
CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions
By China Medical System Holdings Limited · Via ACN Newswire · June 8, 2026
CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer(R) and Cosmofer(R)
By China Medical System Holdings Limited · Via ACN Newswire · April 27, 2026
